Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility Study

Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility Study

We prospectively performed a longitudinal analysis of circulating tumor DNA (ctDNA) from 149 plasma samples and CT scans in Stage III and IV metastatic melanoma patients (<i>n</i> = 20) treated with targeted agents or immunotherapy using two custom next-generation sequencing (NGS) Ion Am...

Full description

Bibliographic Details
Main Authors: Marina Berger, Andrea Thueringer, Doritt Franz, Nadia Dandachi, Emina Talakić, Georg Richtig, Erika Richtig, Peter Michael Rohrer, Lukas Koch, Ingrid Hildegard Wolf, Catharina Koch, Barbara Margaretha Rainer, Maximilian Koeller, Martin Pichler, Hanno Gerritsmann, Karl Kashofer, Ariane Aigelsreiter
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
metastatic melanoma
circulating tumor DNA
next-generation sequencing
custom panels
treatment monitoring
Online Access:https://www.mdpi.com/2072-6694/13/12/3101

Internet

https://www.mdpi.com/2072-6694/13/12/3101

Similar Items